MGP

MGP Full Name

Matrix Gla Protein

MGP Introduction

The small vitamin K-dependent protein Matrix Gla Protein (MGP) exists mainly in vascular smooth muscle cells and cartilage and bone tissue. The protein contains γ-carboxyglutamic acid (Gla) residues which create its strong calcium ion binding ability. The protein MGP undergoes post-translational modification to create a hydroxyapatite-binding protein which stops soft tissue from becoming calcified. MGP functions as a vital controller of tissue mineralization because it enables normal bone development and stops abnormal calcification from happening in blood vessels and cartilage.

Figure 1.Structure, calcium binding function, and activation process of matrix Gla protein (MGP).(Source: Kida Y, et al.; 2022)

MGP functions as a strong inhibitor which blocks vascular and cartilage calcification through its ability to bind calcium crystals and control bone morphogenetic protein (BMP) signaling pathways. MGP functions as a protective system which maintains vascular elasticity through its ability to prevent arterial stiffness and protect cartilage structure. MGP needs vitamin K–activated γ-carboxylation to become active because this process transforms inactive MGP into its active form which stops abnormal mineral accumulation. The body requires MGP to maintain proper mineral balance because its deficiency results in abnormal mineral regulation which affects both skeletal and cardiovascular health.

MGP dysfunction or deficiency in clinical settings leads to multiple pathological conditions. The MGP gene mutations result in Keutel syndrome which affects fewer than 100 people worldwide through its combination of abnormal cartilage calcification and vascular calcification and facial malformations. Patients who lack sufficient functional MGP or have MGP that does not undergo proper γ-carboxylation development of cardiovascular diseases becomes more probable. The protein MGP plays a role in vascular calcification which leads to major complications during diabetes and chronic kidney disease. Scientists study MGP as a biomarker for calcification and cardiovascular risk because they want to develop a method to prevent abnormal tissue mineralization from happening.

Alternate Names for MGP

matrix Gla protein; Cell growth-inhibiting gene 36 protein; MGLAP; NTI; OTTHUMP00000239335; MGP; GIG36; OTTHUMP00000239337

• 1.Kida Y, Yamaguchi I. The vascular protective effect of matrix Gla protein during kidney injury. Front Mol Med. 2022, 2:970744.